Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Tamiflu oseltamivir regulatory update

FDA's Pediatric Advisory Committee voted 8-6 to recommend revising the label of influenza drug

Read the full 148 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE